Opinion|Videos|October 22, 2025

Expanding the Role of Long-Acting Antibiotics in Real-World Infection Management

Long-acting antibiotics have evolved from niche treatments to key tools for preventing hospital admissions and improving infection management efficiency.

Long-acting intravenous antibiotics have become central to infection management strategies aimed at optimizing hospital efficiency. Initially reserved for severe or complicated infections, these agents now serve a broader purpose—preventing admissions, facilitating early discharges, and improving patient throughput. Their prolonged activity allows clinicians to treat serious infections with fewer doses while maintaining therapeutic effectiveness, a shift that aligns with stewardship and resource optimization goals.

Clinical data from large real-world studies have reinforced the effectiveness of long-acting therapies across various infection types. These findings have encouraged clinicians to adopt such regimens more confidently, extending their use beyond traditional skin infections to include conditions like bone, joint, and bloodstream infections. This adaptability underscores their role in modern infection management, particularly for patients at risk of treatment noncompliance.

Despite their benefits, monitoring for infusion-related adverse effects remains essential. Providers routinely educate patients about potential reactions and schedule follow-up assessments to track recovery and identify adverse events. In doing so, health care teams balance convenience with safety, ensuring that expanded antibiotic use continues to reflect best clinical practice and patient-centered care.

Related to this article

FAQ: What You Need to Know About West Nile Virus in 2026
After 2 adults died of West Nile virus in central North Carolina this month, this FAQ explains how the mosquito-borne virus spreads, who faces the greatest risk of severe neuroinvasive disease, and how clinicians can diagnose, manage, and help prevent infection when no vaccine or antiviral treatment exists.
NFID Survey Finds Respiratory Vaccine Gap Driven by Lack of Clarity, Not Hesitancy
The National Foundation for Infectious Diseases (NFID) recently held its respiratory season kick-off, which included the release of its annual respiratory disease survey. This year, the survey revealed the gap between vaccine support and uptake. Robert Hopkins Jr, MD, medical director of NFID delves deeper into the findings of the survey and the vaccine uptake challenges associated with certain immunizations.